PET-MRI in Diagnosing Patients With Colon or Rectal Cancer
NCT ID: NCT01807117
Last Updated: 2021-05-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2013-04-30
2014-03-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment
NCT02618850
Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer
NCT03764137
Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer
NCT02117466
A Phase I Study of MLN6907 in Patients With Metastatic Colorectal
NCT02056015
Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer.
NCT01691391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To test the diagnostic performance of PET- MRI in the staging of preoperative high-grade rectal cancer patients, defined by T3 stage or higher or N1 stage or higher or presence of metastasis, that are referred to PET-CT and MRI.
II. To test the diagnostic performance of PET-MRI the follow up of colorectal cancer patients that are referred to PET-CT with or without a diagnostic MRI request by their physicians.
SECONDARY OBJECTIVES:
I. To test different attenuation correction MR sequences and novel diagnostic MR sequences.
OUTLINE:
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic (PET-CT and PET-MRI)
Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
positron emission tomography
Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography
Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging
Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18
Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
positron emission tomography
Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
computed tomography
Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
magnetic resonance imaging
Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
fludeoxyglucose F 18
Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PET-CT should be requested by a referring physician; in the case of having an MR requested as well, it will be reported from the MRI images generated in the PET-MRI
* Stable physical medical conditions to undergo a MRI
* Informed consent must be given and signed prior to study enrollment
* Subjects who have a pacemaker
* Subjects who have a metallic prostheses either in the pelvis or in the abdomen that will interfere with the MR imaging of that anatomical area
* Subjects who suffer from claustrophobia
* Pregnant women
* Cognitive impairment that affects the subject's ability to give consent
Exclusion Criteria
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Case Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raj Paspulati, MD
Role: PRINCIPAL_INVESTIGATOR
Case Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2013-00511
Identifier Type: REGISTRY
Identifier Source: secondary_id
CASE8212
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.